Sign In
Buy AKTS
$28.70
+1.69 (+6.26%)
At Close: Jun 24, 2026
Aktis Oncology: Mini-Proteins With A Targeted Punch
10:02am, Thursday, 11'th Jun 2026
Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4, wi
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
04:05pm, Wednesday, 27'th May 2026
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiophar
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
04:10pm, Wednesday, 13'th May 2026
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
04:01pm, Monday, 11'th May 2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop
Aktis Oncology to Present at the BofA Securities Health Care Conference
08:00am, Wednesday, 06'th May 2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiophar
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting
04:40pm, Tuesday, 28'th Apr 2026
Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b Pa
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
10:55am, Friday, 17'th Apr 2026
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
08:00am, Thursday, 16'th Apr 2026
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radioph
Brokerages Set Aktis Oncology (NASDAQ:AKTS) PT at $32.00
01:09am, Monday, 06'th Apr 2026
Shares of Aktis Oncology (NASDAQ: AKTS - Get Free Report) have been given an average rating of "Buy" by the five research firms that are presently covering the stock, MarketBeat.com reports. Five equi
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radioph
Aktis Oncology (NASDAQ:AKTS) Reaches New 52-Week Low – Should You Sell?
02:39am, Sunday, 29'th Mar 2026
Aktis Oncology (NASDAQ: AKTS - Get Free Report) shares reached a new 52-week low on Friday. The company traded as low as $16.61 and last traded at $16.5650, with a volume of 49406 shares trading hands
Aktis Oncology to Present at Upcoming March Investor Conferences
04:05pm, Tuesday, 24'th Feb 2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to larg
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
08:00am, Tuesday, 24'th Feb 2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to larg
